AI assistant
IDEAYA Biosciences, Inc. — Director's Dealing 2021
Oct 7, 2021
31547_dirs_2021-10-07_f287ece7-69dd-48f9-8dca-b56b3e684c75.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEAYA Biosciences, Inc. (IDYA)
CIK: 0001676725
Period of Report: 2021-10-04
Reporting Person: Dillon Michael P. (SVP, Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-04 | Common Stock | M | 1500 | $11.08 | Acquired | 80289 | Direct |
| 2021-10-04 | Common Stock | S | 500 | $25.8480 | Disposed | 79789 | Direct |
| 2021-10-04 | Common Stock | S | 1000 | $26.6210 | Disposed | 78789 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-10-04 | Stock Option (Right to Buy) | $11.08 | M | 1500 | Disposed | 2029-03-13 | Common Stock (1500) | Direct |
Footnotes
F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2: This transaction was executed in multiple trades in prices ranging from $25.39 to $26.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: This transaction was executed in multiple trades in prices ranging from $26.42 to $26.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: 25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.